More setbacks for Biogen: state's largest hospital system spurns Alzheimer's drug

The state's largest health care provider has declined to administer Biogen Inc.'s new Alzheimer's drug, citing concerns over its safety and efficacy months after a controversial FDA approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.